Augmentation of antipsychotics with levodopa - fMRI study to examine neurobiological effects of L-dopa in Schizophrenia

Dr Naren P Rao0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•(i) SCID-confirmed (Structured Clinical Interview for DSM-IV Axis I
•Disorders) diagnosis of schizophrenia
•(ii) ages 18-55
•(iii) treatment with antipsychotic
•monotherapy; antipsychotic dose within, but not below or exceeding, current recommended

•(i) history of substance abuse or dependence within 3 months
•(ii)positive urine drug screen;
•(iii) history or evidence of any disorder that might adversely
•influence cognitive measures (e.g. mental retardation);
•(iv) presence of serious neurological or
•general medical condition (e.g., Parkinsonâ??s disease, cardiac arrhythmia, epilepsy);
•(v) clinical
•or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, hepatic,
•pulmonary (including bronchial asthma), or renal disease, narrow-angle glaucoma, malignant
•(vi) pregnancy/nursing
•(vii) nonselective monoamine oxidase (MAO) inhibitors
•within 2 weeks or use of a sympathomimetic amine;
•(viii) evidence of acute psychotic
•exacerbation in the last month;
•(x) acute suicidal risk;
•(xi) change in dose of current
•antipsychotic or concomitant psychotropic medications in the 8 weeks prior to study entry;
•(xii)presence of depressive symptoms, as defined by score >2 on 50% of items (â??moderateâ??), using
•the Calgary Depression Scale
•(xiii) parkinsonian symptoms, as defined by a score >8 on the
•Simpson-Angus Scale for Extrapyramidal Symptoms.

发起方

Dr Naren P Rao